|
Characteristics
|
Rheumatoid arthritis
|
Spondyloarthritides
|
|---|
| |
Synovial fluid
|
Peripheral blood
|
Synovial fluid
|
Peripheral blood
|
|---|
| |
( n = 7)
|
( n = 14)
|
( n = 11)
|
( n = 30)
|
|---|
|
Age, years
|
34.8 ± 12.4
|
53.4 ± 14.5
|
32.4 ± 11.0
|
35.8 ± 13.2
|
|
Disease duration, years
|
4.4 ± 7.6
|
2.6 ± 8.2
|
6.6 ± 5.2
|
6.09 ± 5.91
|
|
ESR, mm/hour
|
59.3 ± 13.8
|
52.2 ± 26.0
|
36.8 ± 20.2
|
27.7 ± 21.5
|
|
CRP, mg/mL
|
6.1 ± 4.9
|
5.4 ± 1.6
|
3.6 ± 2.7
|
2.3 ± 3.2
|
|
RF
|
6/7+
|
12/14+
|
4/4-
|
11/11-
|
|
Anti-CCP
|
4/7+
|
8/14+
|
3/3-
|
4/4-
|
|
HLA-B27
|
Not done
|
Not done
|
7/9+
|
21/26+
|
|
DAS28 score
|
5.6 ± 1.4
|
5.4 ± 1.8
| | |
|
BASDAI score
| | |
2.3 ± 2.1
|
3.9 ± 2.6
|
|
DMARDs, n
|
All patients
|
12
|
3
|
None
|
- aESR = erythrocyte sedimentation rate; CRP = C-reactive protein; RF = rheumatoid factor; anti-CCP = anticyclic citrullinated peptide antibodies; HLA-B27 = human leucocyte antigen B27; DAS28 = disease activity score in 28 joints; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index (measured in AS patients only); DMARDs = disease-modifying antirheumatic drugs. Data are expressed as means ± standard deviations unless otherwise indicated.
